
312 companies racing for a $72B market. Our Enterprise AI transforms trials into actionable intelligence—with full traceability and zero hallucinations.
You're piecing together data from 5 different sources—none of them complete.
By the time you react, the narrative has shifted.
The ratio should be flipped.
But hallucinations and untraceable outputs make them unusable for regulatory-grade decisions.
Here's what happens when Enterprise AI handles the heavy lifting.
AI monitors 828 active NSCLC trials. Get precise positioning for your EGFR, ALK, KRAS G12C, or IO asset, no manual compilation needed.
AI-powered pattern recognition tracks protocol amendments, endpoint changes, and enrollment signals in real-time.
Automated benchmarking against HTA-winning endpoints. Evidence synthesis that takes weeks—delivered in hours.
Every output traces to source—ClinicalTrials.gov, EudraCT, published literature. Zero hallucinations. Audit-ready.
Teams use Knolens to move from "We think this is the landscape" → "We know exactly where we stand."
Never Scramble Before a Board Meeting Again
Know Exactly Who's Targeting Your Patient Population
Get CI, Clinical, and BD on the Same Page in Hours
Spot Threats 3-6 Months Before They Hit
Knowledge graph ensures every insight traces to verified sources
Enterprise scale without enterprise cloud costs
Automates monitoring, alerting, benchmarking, synthesis
Outputs formatted for HTA submissions and board reporting
Knolens fits naturally into existing workflows.
It avoids adding reporting overhead or requiring teams to learn new systems, serving as the central intelligence layer that connects strategy, development, and commercial functions.
Each subtype is its own battlefield—different leaders, endpoints, and payer expectations.
Select your molecular subtype and we'll show you exactly how many competitors are in your space.
See how Knolens tracks NSCLC trials, competitors, and positioning in real time.
Join biotech teams across global organizations making faster, more confident strategic decisions with continuous competitive intelligence.
Trusted by leading global biotech and pharma teams worldwide.
Built for indication-focused decision-making, driving clinical and commercial strategy.
Powered by Knolens' AI, grounded in regulatory-grade data sources.
Developed by Pienomial, a life sciences tech company for AI-native biotech decision support.

Know Your Competitive Position—Before It Shifts
Design Trials Built to Succeed
Our AI handles the complexity so you can focus on decisions
Share your target, mechanism, and stage. AI configures your competitive view in 24 hours.
Comprehensive intelligence: trial comparisons, endpoint benchmarks, positioning opportunities—all traced to source.
Real-time alerts. Monthly AI briefings. Evidence ready for board meetings, payer negotiations, and submissions.
Your competitors are making moves right now. In 15 minutes, you'll know exactly what they are—and how to stay ahead.
"We were preparing for our Phase 3 readout and Knolens flagged that a competitor had quietly amended their protocol to add our same endpoint.
We adjusted our positioning 3 months before their data dropped. That insight alone saved our launch strategy."VP, Competitive Intelligence: Mid-cap Oncology Biotech
Zero
Hallucinations
80%
Less Manual Work
10x
Faster Synthesis
24hr
Setup Time
Get a 15-minute briefing on your specific competitive position.
See how Enterprise AI transforms trial data into strategic intelligence—with full traceability.
Limited to 5 companies per month to ensure personalized attention.
Stop Guessing Where Your NSCLC Asset Stands